基于酪氨酸磷酸酶(PTP1B)的Ⅱ型糖尿病药物设计、合成和体外活性及毒性的初步评价

doi:10.6023/A15090597

化学学报 ›› 2016, Vol. 74 ›› Issue (2): 155-164.DOI: 10.6023/A15090597 上一篇下一篇

研究论文

基于酪氨酸磷酸酶(PTP1B)的Ⅱ型糖尿病药物设计、合成和体外活性及毒性的初步评价

卢骋^a, 刘祥^b, 唐延婷^b, 徐永学^b, 仲威龙^a, 孙涛^a, 周红刚^a

a 药物化学生物学国家重点实验室南开大学药学院和天津市分子药物研究重点实验室天津 300071;
b 天津国际生物医药联合研究院高通量药物筛选中心天津 300457

投稿日期:2015-09-11 发布日期:2015-12-23
通讯作者: 周红刚 E-mail:honggang.zhou@nankai.edu.cn
基金资助:
项目受国家生物医药国际创新园专项基金(Nos.11ZCKFSY06900,10ZCKFSY08600,14ZCZDSY00038)和国家自然科学基金(No.81102374)资助.

Design, Synthesis of a Novel Phosphatase 1B Inhibitor and the Evaluation of Its Biology Activity and Toxicity in vitro

Lu Chenga^a, Liu Xiang^b, Tang Yanting^b, Xu Yongxue^b, Zhong Weilong^a, Sun Taoa^a, Zhou Honggang^a

a State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071;
b High Throughput Molecular Drug Discovery Center, Tianjin International Joint Academy of Biotechnology and Medicine, Tianjin 300457

Received:2015-09-11 Published:2015-12-23
Supported by:
Project supported by the National Natural Science Foundation of China (No. 81102374) and the National Biomedical Special Project of International Innovation Park (Nos. 11ZCKFSY06900, 10ZCKFSY08600, 14ZCZDSY00038).

文章分享

1. 基于酪氨酸磷酸酶(PTP1B)的Ⅱ型糖尿病药物设计、合成和体外活性及毒性的初步评价.PDF(858KB)

摘要/Abstract

酪氨酸磷酸酶PTP1B已被公认为治疗Ⅱ型糖尿病药物的理想靶标蛋白.通过重组表达制备PTP1B蛋白及其蛋白质晶体,并尝试将其与768种小分子片段进行以结构为基础的筛选,得到了数个与PTP1B结合的小分子片段及其化学结构.在此基础上利用计算机辅助药物设计方法设计与优化出一种新型PTP1B抑制剂,并经13步反应合成了该目标分子.体外药理活性和毒性的初步评价的结果表明,其对体外重组人源PTP1B的酪氨酸磷酸酶活性半数抑制浓度IC50值达到(3.4±1.2) μmol/L,优于阳性对照;在HepG2细胞胰岛素抵抗模型中,该化合物能有效改善胰岛素抵抗细胞对葡萄糖的利用能力,其改善效果与阳性药匹格列酮相当.初步的斑马鱼毒性检测表明,目标该化合物在浓度为500μmol/L时未对幼鱼产生明显毒性.新化合物的发现为新型PTP1B抑制剂的后续开发开辟了新基础.

关键词: 酪氨酸磷酸酶PTP1B, X射线晶体衍射, 计算机辅助药物设计, 合成, 活性

Protein tyrosine phosphatase 1B (PTP1B) is an enzyme that downregulates the insulin receptor. It has been considered as one of the drug targets of diabetes, and the inhibitors for PTP1B to treat type II diabetes have received considerable attention. The study reports a discovery of a new lead compound inhibiting PTP1B. In this work, PTP1B protein was expressed, purified and crystallized to the resolution of 2.1 Angstrom in the condition of 19%~21% PEG8000, 200 mmol/L Mg(Ac)₂·4H₂O. Structural based fragment screening was then performed against 768 fragment chemical compounds. These small molecular fragments were soaked with the PTP1B crystals, and three of them were found to bind at the active site A of PTP1B in the crystals. Then 14 kinds of published molecules which bind to the second active site (site B) were chosen. With the structures of these bound fragment compounds, hundreds of moleculars were calculated by computer aided drug design. Compound 20 was selected as the target compound, and it was synthesized by 13 steps with the total yield of 1.7%. The structure of compound 20 was characterized by ¹H NMR and HRMS data. Bioassay of inhibition of PTP1B by the new compounds revealed its IC₅₀ at (3.4±1.2) μmol/L, which was better than that of the positive control drug-sodium vanadate. The result of measurement of glucose uptake by insulin resistant HepG2 cells showed that the new compound can improve glucose uptake and had similar effect as Pioglitazone. The acute toxicity of the new compound was tested by using zebrafish larvae at two different concentrations (50 and 500 μmol/L). The results showed there was no significant difference in heart rate, blood flow and morphology between the experiment and control group of zebrafish. All the results above implied the new compound has a good inhibition on PTP1B and low acute toxicity. It may be a potential lead compound for further drug discovery.

Key words: protein tyrosine phosphatase (PTPase) 1B, crystal diffraction, structure-based drug design, synthesis, activity

引用此文

卢骋, 刘祥, 唐延婷, 徐永学, 仲威龙, 孙涛, 周红刚. 基于酪氨酸磷酸酶(PTP1B)的Ⅱ型糖尿病药物设计、合成和体外活性及毒性的初步评价[J]. 化学学报, 2016, 74(2): 155-164.

Lu Chenga, Liu Xiang, Tang Yanting, Xu Yongxue, Zhong Weilong, Sun Taoa, Zhou Honggang. Design, Synthesis of a Novel Phosphatase 1B Inhibitor and the Evaluation of Its Biology Activity and Toxicity in vitro[J]. Acta Chim. Sinica, 2016, 74(2): 155-164.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

参考文献

[1] Tonks, N. K. Nat. Rev. Mol. Cell Biol. 2006, 7, 833.
[2] Tonks, N. K.; Diltz, C. D.; Fischer, E. H. J. Biol. Chem. 1988, 263, 6731.
[3] Kenner, K. A.; Anyanwu, E.; Olefsky, J. M.; Kusari, J. J. Biol. Chem. 1996, 271, 19810.
[4] Ahmad, F.; Li, P. M.; Meyerovitch, J.; Goldstein, B. J. J. Biol. Chem. 1995, 270, 20503.
[5] Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A. L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C. C.; Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; Kennedy, B. P. Science 1999, 283, 1544.
[6] Combs, A. P. J. Med. Chem. 2010, 53, 2333.
[7] Barford, D.; Flint, A. J.; Tonks, N. K. Science 1994, 263, 1397.
[8] Renate, R. B.; Dirk, S.; Elke, H. H.; Atanas, G. A.; Markus, G.; Hermann, S.; Verena, M. D. Nat. Prod. 2010, 73, 1578.
[9] Shen, K.; Keng, Y. F.; Wu, L.; Guo, X. L.; Lawrence, D. S.; Zhang, Z. Y. J. Biol. Chem. 2001, 276, 47311.
[10] Asante-Appiah, E.; Patel, S.; Dufresne, C.; Roy, P.; Wang, Q.; Patel, V.; Friesen, R. W.; Ramachandran, C.; Becker, J. W.; Leblanc, Y.; Kennedy, B. P.; Scapin, G. Biochemistry 2002, 41, 9043.
[11] Sun, J. P.; Fedorov, A. A.; Lee, S. Y.; Guo, X. L.; Shen; Lawrence, D. S.; Almo, S. C.; Zhang, Z. Y. J. Biol. Chem. 2003, 278, 12406.
[12] Szczepankiewicz, B. G.; Liu, G.; Hajduk, P. J.; Abad-Zapatero, C.; Pei, Z.; Xin, Z.; Lubben, T. H.; Trevillyan, J. M.; Stashko, M. A.; Ballaron, S. J.; Liang, H.; Huang, F.; Hutchins, C. W.; Fesik, S. W.; Jirousek, M. R. J. Am. Chem. Soc. 2003, 125, 4087.
[13] Xin, Z.; Oost, T. K.; Abad-Zapatero, C.; Hajduk, P. J.; Pei, Z.; Szczepankiewicz, B. G.; Hutchins, C. W.; Ballaron, S. J.; Stashko, M. A.; Lubben, T.; Trevillyan, J. M.; Jirousek, M. R.; Liu, G. Bioorg. Med. Chem. Lett. 2003, 13, 1887.
[14] Liang, N.; Li, Y. N.; Ge, Z. Q. Acta Chim. Sinica 2009, 67, 735. (梁娜娜, 李艳妮, 葛志强, 化学学报, 2009, 67, 735.)
[15] Liu, G.; Xin, Z. L.; Pei, Z. G.; Hajduk, P. J.; Abad-Zapatero, C.; Hutchins, C. W.; Zhao, H. Y.; Lubben, T. H.; Ballaron, S. J.; Haasch, D. L.; Kaszubska, W.; Rondinone, C. M.; Trevillyan, J. M.; Jirousek, M. R. J. Med. Chem. 2003, 46, 4232.
[16] Zhou, X. W.; Tang, Y.; Sang, F.; Zhang, X.; Li, L.; Zhou, H.; Liu, W.; Dai, Y. Chin. J. Org. Chem. 2015, 35, 1363. (周晓伟, 唐延婷, 桑锋, 张秀利, 李立新, 周红刚, 刘伟, 戴玉洁, 有机化学, 2015, 35, 1363.)
[17] Wilson, D. P.; Wan, Z. K.; Xu, W. X.; Kirincich, S. J.; Follows, B. C.; Joseph-McCarthy, D.; Foreman, K.; Moretto, A.; Wu, J.; Zhu, M.; Binnun, E.; Zhang, Y. L.; Tam, M.; Erbe, D. V.; Tobin, J.; Xu, X.; Leung, L.; Shilling, A.; Tam, S. Y.; Mansour, T. S.; Lee, J. J. Med. Chem. 2007, 50, 4681.
[18] Craig, C. M.; Jaqueline, D. H.; Marjorie, A. J.; Zaneta, D.; Emily, A. B.; Bradley, A. G.; Nicole, A. D.; Mary, A. Y.; Lisa, M. M. J. Inorg. Biochem. 2010, 104, 274.
[19] Dong, L. J.; Jin, Y. Z.; Shi, L.; Song, G. M. J. Third Mil. Med. Univ. 2012, 34, 671. (董瓅瑾, 晋玉章, 石磊, 宋光明, 第三军医大学学报, 2012, 34, 671.)
[20] Huang, D.; Liu, Y.; Shi, B.; Li, Y.; Wang, G.; Liang, G. J. Mol. Graphics Modell. 2013, 45, 65.

基于酪氨酸磷酸酶(PTP1B)的Ⅱ型糖尿病药物设计、合成和体外活性及毒性的初步评价

Design, Synthesis of a Novel Phosphatase 1B Inhibitor and the Evaluation of Its Biology Activity and Toxicity in vitro

PDF

补充材料

可视化

被引次数

摘要/Abstract

引用此文

分享此文

参考文献

相关文章 15

编辑推荐

相关统计

本文评价

[1]	杨铃悦, 李赟婷, 舒超. 亚磺酸内酯研究进展[J]. 化学学报, 2024, 82(2): 171-189.
[2]	廖晨宇, 郭山巍, 黄美薇, 郭勇, 陈庆云, 刘超, 张运文. 氟醚磷酸胆碱的合成及性能研究[J]. 化学学报, 2024, 82(1): 46-52.
[3]	车飞达, 赵晓茗, 张馨, 丁琪, 王昕, 李平, 唐波. 抑郁症相关活性分子的荧光成像^★[J]. 化学学报, 2023, 81(9): 1255-1264.
[4]	万义, 何江华, 张越涛. Lewis酸碱对催化极性烯烃单体精准聚合的研究进展^★[J]. 化学学报, 2023, 81(9): 1215-1230.
[5]	陈其文, 张先正. 纳米酶介导的炎性肠道疾病治疗研究进展^★[J]. 化学学报, 2023, 81(8): 1043-1051.
[6]	洪梅, 高金强, 李彤, 杨世和. 原位刻蚀调控多级孔分子筛策略及其应用进展^★[J]. 化学学报, 2023, 81(8): 937-948.
[7]	张媛, 郑贝宁, 符美春, 冯守华. 尖晶石氧化物在肿瘤诊疗应用领域研究进展^★[J]. 化学学报, 2023, 81(8): 949-954.
[8]	甘绍艳, 钟晟昱, 王力廷, 史雷. 有机高价溴试剂的合成及其应用研究[J]. 化学学报, 2023, 81(8): 1030-1042.
[9]	郑文山, 高冠斌, 邓浩, 孙涛垒. Ag₂Se@Ag₂S核壳量子点的室温合成及其近红外荧光性能优化[J]. 化学学报, 2023, 81(7): 763-770.
[10]	张艳东, 朱守非. 环丙烷骨架膦配体的研究展望^★[J]. 化学学报, 2023, 81(7): 777-783.
[11]	坎比努尔•努尔买买提, 王超, 罗时玮, 阿布都热西提•阿布力克木. 电化学条件下α,α,α-三卤(氯, 溴)甲基酮类化合物的选择性脱卤反应研究[J]. 化学学报, 2023, 81(6): 582-587.
[12]	蔡新红, 陈建中, 张万斌. 镍催化不对称氢化构建手性C—X键的研究进展^★[J]. 化学学报, 2023, 81(6): 646-656.
[13]	刘坜, 郑刚, 范国强, 杜洪光, 谭嘉靖. 4-酰基/氨基羰基/烷氧羰基取代汉斯酯参与的有机反应研究进展[J]. 化学学报, 2023, 81(6): 657-668.
[14]	王俊, 许晓梅, 周姣龙, 赵雅男, 孙秀丽, 唐勇, 何素芳, 杨红梅. 新型无硫无磷醚-酯化合物的合成及其作为无灰摩擦改进剂的性能研究[J]. 化学学报, 2023, 81(5): 461-468.
[15]	齐学平, 王飞, 张健. 后合成法构筑钛基金属有机框架及其应用[J]. 化学学报, 2023, 81(5): 548-558.